ALLO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Allogene Therapeutics Inc (ALLO) is not a strong buy at this moment for a beginner investor with a long-term strategy. Despite recent analyst upgrades and potential long-term catalysts, the company is facing significant financial challenges, insider selling, and a lack of immediate positive momentum. Holding or looking for better opportunities is recommended.
The technical indicators are mixed. The MACD is negative and expanding downward, suggesting bearish momentum. RSI is neutral at 41.524, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock is trading close to its support level of 1.58, indicating potential downside risk. Resistance levels at 1.905 and 2.005 are far from the current price of 1.62.
Analysts have recently upgraded the stock with optimistic price targets of $5 and $8, citing confidence in clinical trial timelines and potential $1B peak sales by
The stock has an 80% chance to gain 7.62% in the next month based on historical patterns.
Insiders are selling heavily, with a 723.44% increase in selling activity over the last month.
Financial performance is weak, with declining net income (-37.55% YoY), EPS (-40.62% YoY), and gross margin (-100% YoY).
No recent news or significant events to drive short-term momentum.
The company reported no revenue growth in Q3 2025, with net income dropping to -$41.4M (-37.55% YoY) and EPS declining to -0.19 (-40.62% YoY). Gross margin fell to 0, indicating severe financial struggles.
Analysts are optimistic, with recent upgrades to 'Outperform' and 'Buy' ratings and price targets of $5 and $8. They highlight confidence in clinical trial progress and long-term sales potential. However, these are long-term projections with no immediate catalysts.
